-
1
-
-
84876005284
-
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
-
Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
-
(2013)
Sci Transl Med.
, vol.5
, Issue.177
-
-
Brentjens, R.J.1
Davila, M.L.2
Riviere, I.3
-
2
-
-
84876325876
-
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
-
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
-
(2013)
N Engl J Med.
, vol.368
, Issue.16
, pp. 1509-1518
-
-
Grupp, S.A.1
Kalos, M.2
Barrett, D.3
-
3
-
-
84890827981
-
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
-
Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-4139.
-
(2013)
Blood.
, vol.122
, Issue.25
, pp. 4129-4139
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Carpenter, R.O.3
-
4
-
-
84863337890
-
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
-
Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
-
(2012)
Blood.
, vol.119
, Issue.12
, pp. 2709-2720
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Feldman, S.A.3
-
5
-
-
84901711201
-
Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 chimeric antigen receptor [ASH abstract 168]
-
Kochenderfer JN, Dudley ME, Kassim SH, et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 chimeric antigen receptor [ASH abstract 168]. Blood. 2013;122(21)(suppl).
-
(2013)
Blood.
, vol.122
, Issue.21 SUPPL.
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Kassim, S.H.3
-
6
-
-
84877575144
-
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
-
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-276.
-
(2013)
Nat Rev Clin Oncol.
, vol.10
, Issue.5
, pp. 267-276
-
-
Kochenderfer, J.N.1
Rosenberg, S.A.2
-
7
-
-
78549278144
-
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
-
Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
-
(2010)
Blood.
, vol.116
, Issue.20
, pp. 4099-4102
-
-
Kochenderfer, J.N.1
Wilson, W.H.2
Janik, J.E.3
-
8
-
-
80051720194
-
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
-
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
-
(2011)
N Engl J Med.
, vol.365
, Issue.8
, pp. 725-733
-
-
Porter, D.L.1
Levine, B.L.2
Kalos, M.3
Bagg, A.4
June, C.H.5
|
